Nuvation Bio Q2 Revenue Beats Estimates as IBTROZI Sales Jump 25%
NUVB has more than doubled off its 52-week low of $2.18.
Summary
Nuvation Bio reported Q2 revenue of $31.69 million, beating the $27.51 million consensus, driven by a 25% sequential increase in IBTROZI net product revenue. The drug's adoption in ROS1+ NSCLC, particularly among TKI-naïve patients, is accelerating. Collaboration and license revenue also rose on higher product supply and royalties. The company posted a net loss of $62.8 million, or $0.18 per share, as operating expenses climbed on expanded clinical trials and headcount. This follows the $250 million convertible note offering completed in early July, which strengthened the balance sheet ahead of this commercial ramp. No forward guidance was provided, but the revenue beat and IBTROZI momentum suggest the launch is tracking ahead of expectations.
At the time of this announcement, NUVB was trading at $6.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $2.18 to $9.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.